newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

  • Ascentage Pharma Group International announced that results from two clinical studies of lisaftoclax (APG-2575) were selected for presentations, including an oral report, at the 67th ASH Annual Meeting in Orlando, Florida, from December 6-9, 2025.
  • This marks the fourth consecutive year that data on lisaftoclax has been selected by the ASH Annual Meeting, with this year featuring data on three investigational candidates: lisaftoclax, olverembatinib, & APG-5918.
  • The oral presentation (Abstract #88) details results from a registrational Phase II study of lisaftoclax monotherapy in relapsed/refractory CLL/SLL patients who failed BTK inhibitors, showing an objective response rate (ORR) of 62.5% & median progression-free survival of 23.89 months.
  • The poster presentation (Abstract #1641) reports data from the APG2575AU101 study of lisaftoclax combined with azacitidine in myeloid malignancies, demonstrating an ORR of 40.4% in relapsed/refractory AML/MPAL & 80.0% in newly diagnosed higher-risk MDS/CMML.
  • Lisaftoclax is an orally available Bcl-2 inhibitor currently commercialized in China for adult CLL/SLL patients who have received prior systemic therapy including BTK inhibitors, with four global registrational Phase III trials currently underway.
  • The company also presented multiple studies on olverembatinib covering efficacy in TKI-resistant CML, Ph+ ALL, & real-world transplantation outcomes, alongside preclinical data on APG-5918 for multiple myeloma.
  • Dr. Yifan Zhai, Chief Medical Officer, stated that lisaftoclax has shown efficacy & manageable safety profiles across numerous studies & emphasized the company's commitment to accelerating clinical development programs.
  • All drug candidates mentioned are under investigation & have not yet received FDA approval in the US, though olverembatinib & lisaftoclax hold NMPA approval for specific indications in China.